A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Anti-CD19/CD22-chimeric-antigen-receptor-T-cell-therapy-Shanghai-Unicar-Therapy-Bio-medicine-Technology (Primary) ; Cyclophosphamide
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2021 New trial record